Remodulin (treprostinil sodium)
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Mar 1, 2005 → Oct 1, 2005
NCT ID
NCT00494533About Remodulin (treprostinil sodium)
Remodulin (treprostinil sodium) is a approved stage product being developed by United Therapeutics for Pulmonary Arterial Hypertension. The current trial status is terminated. This product is registered under clinical trial identifier NCT00494533. Target conditions include Pulmonary Arterial Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Arterial Hypertension were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00494533 | Approved | Terminated |
Competing Products
20 competing products in Pulmonary Arterial Hypertension